Intuitive (ISRG) Q2 2026 earnings review
da Vinci 5 Boom Powers Strong Q2, Tariff Refund Masks Margin Reality
Intuitive Surgical delivered a highly robust Q2 2026, with revenue climbing 19% YoY to $2.89B and non-GAAP EPS surging 28% to $2.80. The adoption of the new da Vinci 5 system is officially a supercycle, accounting for over half of all quarterly system placements and driving the installed base up 12%. However, the headline non-GAAP gross margin of 70.0% was artificially inflated by a $36M gross retroactive tariff refund. Adjusting for this, underlying profitability remains tightly bound to the 68-69% range as international headwinds and supply chain costs persist. Still, 16% global procedure growth confirms the core recurring revenue engine is unbothered by macro noise.
🐂 Bull Case
The dV5 upgrade cycle is pulling in massive capital demand. The company placed 246 dV5 systems in Q2 (up from 232 in Q1), completely overshadowing older models and defending pricing power.
Instruments and Accessories (I&A) revenue grew 18% to $1.73B, fueled by steady 16% global procedure growth. The installed base expansion guarantees a durable stream of high-margin consumables.
🐻 Bear Case
Despite a strong clinical narrative, Ion procedure volume growth decelerated for the fourth consecutive quarter, dropping to 36% YoY from a peak of 52% a year ago.
Excluding the one-time $35.9M gross IEEPA tariff refund, core manufacturing and tariff costs continue to pressure margins. The company maintained a 68-69% FY margin guide, signaling the 70.0% print is a one-off.
⚖️ Verdict: 🟢
Bullish. Intuitive continues to demonstrate total market dominance. While margin noise and slowing Ion growth bear watching, a 19% top-line growth rate at a $10B+ run-rate scale, driven by a highly successful new hardware launch, is exceptional.
Key Themes
The da Vinci 5 Supercycle is Here
The market transition to the da Vinci 5 system is happening rapidly. Intuitive placed 468 total da Vinci systems in Q2, of which 246 were dV5 models. This compares to 180 dV5 placements in the prior-year quarter. This cycle is not just replacing old systems; it's expanding overall capacity, allowing hospitals to trickle-down older Xi models to alternative care sites like Ambulatory Surgery Centers (ASCs).
Ion Procedure Growth is Decelerating
A clear contradiction to the 'everything is accelerating' narrative is the Ion endoluminal platform. While procedure growth of 36% YoY sounds impressive, it marks a steady, unbroken deceleration from 52% in 25Q2. System placements remained relatively flat at 55 units (vs 54 a year ago). As the installed base law of large numbers kicks in, management will need to expand Ion into new indications to re-accelerate the trajectory.
Tariff Distortions and Macro Margin Baseline
The reported 70.0% Non-GAAP Gross Margin looks like a massive beat compared to recent quarters (67.8% in Q1). However, Q2 results included a retroactive $35.9M gross benefit to Cost of Revenue ($28M net of tax) from IEEPA tariff refunds. Without this, margins would have landed squarely in the 68% range. Management explicitly left their full-year guidance at 68-69%, warning that if additional tariffs are enacted, the impact could be 'material'. Investors should not view 70% as the new baseline.
Digital Expansion and AI Data Foundations
While not directly broken out in revenue lines yet, Intuitive is heavily monetizing digital integration. The da Vinci 5 system acts as a massive data-collection node (kinematics, force feedback, video). By packaging this with the 'My Intuitive+' subscription ecosystem, the company is building a moat against emerging robotic competitors, establishing AI-driven clinical insights that hardware alone cannot replicate.
Lease Models Smooth Capital Constraints
Of the 468 da Vinci placements this quarter, 254 (54%) were under operating leases, and 131 of those were usage-based. This represents an increase in lease mix compared to 49% in 25Q2. While leasing delays upfront revenue recognition, it effectively neutralizes hospital CapEx budget constraints (a known headwind in Europe and Asia) and locks customers into long-term, high-margin recurring arrangements.
Other KPIs
Accelerating/Stable. Up 18% YoY, mirroring the 16% total procedure growth and demonstrating robust pricing power. This high-margin segment remains the lifeblood of the company, representing 60% of total quarterly revenue.
Stable. Up $650M sequentially despite returning $380M to shareholders via stock repurchases (0.9 million shares). The fortress balance sheet provides massive flexibility for future M&A, R&D, or aggressive buybacks if the stock dips.
Guidance
Decelerating. Q2 actual procedure growth was 16%, so this full-year guide implies a slight slowdown in the second half of 2026. Management notes they expect to land near the midpoint (~14.5%), factoring in standard conservatism around macro headwinds, hospital staffing, and international budgets.
Stable. Despite Q2 printing at 70.0% due to the retroactive tariff refund, management maintained this range. It explicitly bakes in a 1.0% headwind from current tariffs. Achieving this implies the company is successfully managing the dilutive mix-shift of newer platforms (dV5 and Ion) rolling off the assembly line.
Stable. Demonstrates excellent operating leverage. With revenue growing at 19%, holding OpEx growth to 11-13% ensures outsized profitability drops straight to the bottom line.
Key Questions
Ion Maturation or Saturation?
Ion procedure growth has decelerated sequentially for four straight quarters, landing at 36% in Q2. Is this simply the law of large numbers, or are we seeing a ceiling on early lung cancer diagnostic penetration before new indications (like ROSE/EBUS) are fully integrated?
Margin Baseline ex-Tariff Refund
Q2 Non-GAAP gross margin hit 70.0%, but included a $35.9M gross benefit from past tariff refunds. Can management walk through the exact structural margin performance for the quarter, and how much further optimization is needed to sustain 69%+ without these one-time benefits?
International Capital Headwinds
With the US market rapidly absorbing the da Vinci 5, what is the latest status on capital budget constraints in China and Japan? Are these markets delaying overall portfolio upgrades, or opting heavily into the refurbished XiR tiers?